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Abstract 
Background: This study was designed to derive and validate a score to predict early ischemic 
events and major bleedings after an acute ischemic stroke in patients with atrial fibrillation (AF).  
Methods: The derivation cohort consisted of 854 patients with acute ischemic stroke and AF 
included in prospective series between January 2012 and March 2014. Older age (HR 1.06 for each 
additional year, 95% CI 1.00-1.11) and severe atrial enlargement (HR 2.05, 95% CI 1.08-2.87) were 
predictors for ischemic outcome events (stroke, transient ischemic attack, systemic embolism) at 
90 days from acute stroke. Small lesions (≤1.5 cm) were inversely correlated with both major 
bleeding (HR 0.39, p=0.03) and ischemic outcome events (HR 0.55, 95% CI 0.30-1.00). We assigned 
to age 80 years 2 points and between 70-79 years 1 point; ischemic index lesion >1.5 cm 1 point; 
severe atrial enlargement 1 point (ALESSA score). A logistic regression with the ROC graph 
procedure (C statistic) showed an area under the curve of 0.697 (0.632-0.763), p=0.0001 for 
ischemic outcome events and 0.585 (0.493-0.678), p=0.10 for major bleedings. 
Results: The validation cohort consisted of 994 patients included in prospective series between 
April 2014 and June 2016. Logistic regression with the ROC graph procedure showed an area under 
the curve of 0.646 (0.529-0.763), p=0.009 for ischemic outcome events and 0.407 (0.275-0.540), 
p=0.14 for hemorrhagic outcome events.  
Conclusions: In acute stroke patients with AF, high ALESSA scores were associated with a high risk 
of ischemic events but not of major bleedings.  
 
  
Introduction  
Anticoagulation is highly beneficial for long-term secondary stroke prevention in patients with 
atrial fibrillation (AF); nonetheless, there is a paucity of data addressing when anticoagulation can 
be effectively and safely initiated after acute stroke. Data from the recently published 
observational multicenter RAF study (Early Recurrence and Cerebral Bleeding in Patients With 
Acute Ischemic Stroke and Atrial Fibrillation) suggested that the optimal time for initiating 
anticoagulation treatment for secondary stroke prevention is between 4 to 14 days after an acute 
stroke (1). However, the specific risk/benefit balance for any given patient and which type of 
strokes is associated with the highest risk and benefit by early anticoagulation remains unclear. 
Risk stratification could help to drive clinician decisions on anticoagulant treatment in this clinical 
setting.  
The aim of this prospective multicenter study was to develop and validate a score to predict 
ischemic events and major bleedings at 90 days from an acute ischemic stroke in patients with AF.  
 
Methods  
The risk factors correlated with outcome events were isolated and included in a new risk 
stratification score from a prospective cohort of patients (derivation cohort). The validation of the 
results obtained in the derivation cohort was performed in different patients included in 
prospective series (validation cohort). Patients included in the derivation cohort were not eligible 
for inclusion in the validation cohort. 
Derivation cohort. 
The derivation cohort was extracted from the database of the RAF study, a prospective 
observational study performed between January 2012 and March 2014 which enrolled 
consecutive patients with acute ischemic stroke with either known or newly diagnosed AF. The 
methods and results of RAF study have been described in details (1,2).  
On admission, the severity of acute stroke was assessed using the National Institutes of Health 
Stroke Scale (NIHSS); all investigators were certified about the use of this scale. 
AF was classified as paroxysmal (episodes terminating spontaneously within 7 days), persistent 
(episodes lasting more than 7 days requiring pharmacologic and/or electrical stimulation), or 
permanent (persisting for more than 1 year, either because cardioversion failed or was not 
attempted). 
A cerebral computed tomography (CT) or magnetic resonance (MR) was performed on admission 
in all patients to exclude intracranial hemorrhage. A second cerebral CT scan or MR was 
performed 48–72 h from stroke onset. The sizes of the qualifying infarcts were classified as 
follows: (a) small, when a lesion was ≤1.5 cm, (b) medium-large when a lesion was >1.5 cm. 
Transthoracic echocardiogram was performed within 7 days from index stroke. Left atrial 
enlargement and its severity was defined following the American Society of Echocardiography 
guidelines measuring the left atrial diameter or volume taking into account the difference 
between sexes (3). 
Differences in the characteristics of patients with or without outcome events were tested using χ2 
test. Specifically, univariate tests were applied to compare both clinical characteristics on 
admission and preexisting risk factors for stroke. An exploratory analysis of all variables was 
performed with a divisive hierarchical clustering method. Cluster analysis is used to construct 
smaller groups with similar properties from a large set of heterogeneous data. This form of 
analysis is an effective way to discover relationships within a large number of variables or 
observations; the identification of potential predictors for outcome events was subsequently 
made with a series of multiple logistic regression models. These variables included risk factors, 
reperfusion therapy, severity of stroke on admission according to NIHSS score, CHA2DS2-VASc 
score, and the dimension of the ischemic lesions. The day of starting anticoagulant treatment was 
inserted into the models as a continuous or a dichotomized categorical variable either. 
Description of the risk stratification schema (ALESSA score) 
In the cohort of patients included in the RAF study (derivation cohort), older age (HR 1.06 for 1 
added year, Standard Error 0.0207, Beta-coefficient 0.055, p=0.0025) and severe atrial 
enlargement (HR 2.05, Standard Error 0.389, Beta-coefficient 0.989, p= 0.027), were shown to be 
predictive factors for ischemic outcome events occurring within 90 days from acute stroke. The 
characteristics of the patients in the derivation cohort with and without outcome events are 
described in Tables 1 and 2 of online supplemental files. Small lesions (≤1.5 cm) on CT scan or MRI 
were inversely correlated with both hemorrhagic (HR 0.39, Standard Error 0.491, Beta-coefficient -
1.420, p=0.03) and ischemic outcome events (HR 0.55, Standard Error 0.314, Beta-coefficient -
0.594, p=0.05) (1,2). Based on the magnitude of the effect (Beta-coefficient) associated with these 
variables, we assigned to Age 80 years 2 points; age between 70-79 years 1 point;  the presence 
of an ischemic index LESion >1.5 cm 1 point and presence of Severe Atrial enlargement 1 point 
(ALESSA score).  
Validation cohort 
The validation cohort consisted of 994 ischemic stroke patients with acute stroke and AF seen 
between April 2014 and June 2016 deriving from several international prospective stroke series. 
Patients included in the validation cohort were those with a reported echocardiogram within 7 
days among 1161 consecutive patients. Inclusion criteria, outcome definition and statistical 
analysis were as in the derivation cohort. 
Patients treated with revascularization (systemic rt-PA and/or intravascular thrombectomy), were 
assumed as having a final lesion >1.5 cm if they had a NIHSS 10 prior to treatment (4). 
Definition of outcome events 
Outcome events for this study were: ischemic outcome events [combination of stroke, transient 
ischemic attack (TIA), systemic embolism] and hemorrhagic outcome events (combination of 
symptomatic intracranial bleeding and major extracranial bleeding) occurring within 90 days. 
Stroke was defined as the sudden onset of a new focal neurological deficit of vascular origin in a 
site consistent with the territory of a major cerebral artery and categorized as ischemic. TIA was 
defined as a transient episode of neurological dysfunction caused by focal brain ischemia without 
acute infarction at neuroimaging. Systemic embolism was defined as an acute vascular occlusion 
of an extremity or organ confirmed by imaging, surgery, or autopsy. Hemorrhagic transformation 
found on neuroimaging 24 to 72 hours after onset was not considered an outcome event, unless 
they were symptomatic. Major extracranial bleeding was defined as a reduction in the hemoglobin 
level of at least 2 g per deciliter, requiring a blood transfusion of at least 2 units, or symptomatic 
bleeding in a critical area or organ (5). 
Statistical analysis 
Derivation cohort 
A descriptive analysis with proportions was used to describe the derivation cohort and the event 
rates of ischemic outcome events and hemorrhagic outcome events. The 95% confidence interval 
(CI) of event rates using the binomial approximation was calculated. A logistic regression analysis 
was performed with ALESSA risk factors as independent variables, and ischemic events and major 
intra- and extracranial bleeding as dependent variables. The probability that this model would 
predict the correct classification of individual patients (with or without ischemic or hemorrhagic 
outcome events) was saved. Thereafter, the probabilities in a receiver-operating characteristic 
(ROC) curve against ischemic or hemorrhagic outcome events as dependent variables were 
plotted. The areas under the curves for these ROC curves represent the ability of the ALESSA score 
to correctly classify risks for ischemic or hemorrhagic outcome events, which are also referred to 
as the C-statistic (Harrell’s C) (6). 
Validation cohort 
The same statistical analysis performed in the derivation cohort, was used in the validation cohort.  
 
Results 
Derivation cohort 
In the RAF cohort (Table 1 online supplemental files), high scores of the ALESSA score (3 and 4) 
were correlated with ischemic outcome events but not with hemorrhagic outcome events (Figure 
1). Patient’s characteristics for both cohorts are reported in Table 1. Multivariable analysis 
confirmed that ALESSA score, as continuous variable, was an independent predictor of ischemic 
outcome events (OR 1.83 for 1 added point; 95% CI 1.17-2.87, p=0.08) while it was not correlated 
with hemorrhagic outcome events (OR 1.07 for 1 added point; 95% CI 0.48-2.40, p=0.8). 
Logistic regression with the ROC graph procedure to obtain the c statistic showed that the area 
under the curve was 0.697 (0.632-0.763), p=0.0001 for ischemic outcome events and 0.585 (0.493-
0.678), p=0.10 for hemorrhagic outcome events (figures 2a and 2b). On multivariate regression 
analysis, a score higher than 2 was correlated with ischemic outcome events (OR: 2.5, 95% CI 1.4-
4.4, p=0.001) while it was not correlated with hemorrhagic outcome events (OR: 1.1, 95% CI 0.5-
2.4, P=0.9).  
Validation cohort 
The features of the validation cohort and the relative differences with the derivation cohort are 
shown in Table 1. The main differences between derivation and validation cohorts were that the 
validation cohort had CHA2DS2-VASc score lower compared with the derivation cohort and that 
88% of the patients in the validation cohort were treated with direct anticoagulants compared to 
10% in the derivation cohort. A lower risk of composite outcome event was observed in the 
validation cohort (4.9%) compared to the derivation cohort (11.5%) (Table 2). 
In the validation cohort, high scores of the ALESSA score were correlated with ischemic outcome 
events but not with hemorrhagic outcome events. (Figure 3). Study outcomes are reported in 
Tables 1 and 2. 
Multivariable analysis confirmed that ALESSA score as continuous variable was an independent 
predictor of ischemic outcome events (OR 1.69 for 1 added point; 95% CI 1.00-2.85, p=0.048) 
while it was not correlated with hemorrhagic outcome events (OR 1.19 for 1 added point; 95% CI 
0.68-2.09, p=0.5). 
Logistic regression with the ROC graph procedure to obtain the c statistic showed that the area 
under the curve was 0.646 (0.529-0.763), p=0.009 for ischemic outcome events within 90 days and 
0.407 (0.275-0.540), p=0.14 for hemorrhagic outcome events (figures 4a and 4b).  
On multivariate regression analysis, a score higher than 2 was marginally not associated with 
ischemic outcome events (OR: 2.07, 95% CI 0.93-4.67, p=0.07) while it was not correlated with 
hemorrhagic outcome events (OR: 0.7, 95% CI 0.3-1.8, P=0.4).  
 
Discussion 
In patients with ischemic stroke with AF, the risk of stroke recurrence has been found to be 
particularly high in the first two weeks after the acute event (7). Despite this observation, in these 
patients there are no comparative studies on the optimal timing of starting of anticoagulation. 
Thus, such a decision hinges upon the assessment of the competing risks for early 
thromboembolic recurrences and hemorrhagic transformation.  
The RAF study suggested that in patients with acute stroke and AF, the best time for initiating 
anticoagulation treatment for secondary stroke prevention ranges from 4 to 14 days from stroke 
onset. In patients with acute stroke and AF, clinicians would like to be able to identify those 
patients, who may be candidates to prompt anticoagulation, with a risk of early recurrence high 
enough to justify the risk of cerebral bleeding associated with early anticoagulant treatment. 
Several risk factors could be used to estimate the risk of recurrence or cerebral bleeding (8). In this 
study, a novel risk factor-based approach to stroke risk stratification in patients with acute stroke 
and AF has been validated. Within 90 days from index stroke, patients with ALESSA score between 
0 and 2 have a low risk for both ischemic recurrent events and bleeding. During the same period of 
time, patients with scores 3 or 4 have a statistically significantly increase in the risk of ischemic 
recurrent events but not of the risk of bleeding. These results may be explained by the fact that 
the ALESSA score was built picking up from the derivation cohort the variables correlated with 
ischemic recurrence and not with hemorrhagic transformation. Our clinical interpretation is that 
patients with score 3 or 4 could have the best benefit from an early anticoagulation. The optimal 
time of starting anticoagulant treatment might not be the same with all anticoagulants due to the 
different promptness of action. Indeed, NOACs reach therapeutic level in about 2 hours while 
vitamin K antagonists may take days to achieve it. 
The c-statistic showed a 0.646 predictive value of the ALESSA score for ischemic events. This value, 
although not outstanding, is of the same order of magnitude of the 0.606 predictive value of the 
CHA2DS2-VASc for long-term risk of thromboembolism in patients with AF (9). Notably, CHA2DS2-
VASc score is currently considered the best score to choose the type of antithrombotic treatment 
for long-term stroke prevention in patients with AF. Indeed, in patients with acute stroke and AF, 
it was found that CHA2DS2-VASc score was a predictive factor for ischemic recurrence occurring as 
early as within 90 days from stroke onset (8). However, in this study CHA2DS2-VASc score was a 
predictive factor, along with ischemic recurrent event, of early symptomatic cerebral bleeding. 
Therefore, CHA2DS2-VASc score cannot be used to identify those patients with acute stroke and AF 
who benefit the most of early anticoagulation.  
This study has some limitations. The validation cohort had a lower CHA2DS2-VASc score compared 
with the derivation cohort; furthermore, about 88% of the patients in the validation cohort were 
treated with direct oral anticoagulants compared to about 10% of the patients in the derivation 
cohort. These differences due to different time periods of data collection, probably lead to a lower 
rate of outcome events (the combination of ischemic and hemorrhagic events) in the validation 
cohort compared to the derivation cohort (4.9% versus 10.8% respectively). The low rates of 
events in the validation cohort may have led to reduce statistical power in the study. However, the 
study has the advantage to mirror the changes in clinical practice in this clinical setting. In the 
patients of derivation cohort treated mainly vitamin K antagonists, a key determinant of 
hemorrhagic risk (and also efficacy of infarct prevention) would be the INR. Unfortunately, the INR 
at the moment of the outcome event was not available. 
Our study has also some strengths as the sample size and the prospective design. In view of the 
absence of any randomized trial, the ALESSA score based on simple and easily available variables, 
could assist stroke physicians in better managing acute cerebral ischemia in patients with AF. 
Furthermore, the score may be used as a selection criteria for trials evaluating early 
anticoagulation in patients acute stroke and AF. 
Conclusions  
ALESSA is a novel, simple risk stratification score for patients with acute stroke and AF based on 
age, lesion size and the presence of severe atrial enlargement. High scores of this schema are 
associated with the risk of ischemic recurrent events but not with bleeding. Therefore, patients 
with acute stroke and AF and an ALESSA score higher than 2 are candidates to an early 
anticoagulation treatment.  
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 Figure legends 
Figure 1 
The risk of ischemic outcome events and symptomatic intracranial bleedings / major extracranial 
bleeding according to ALESSA score in the derivation cohort. 
 
Figure 2 
Logistic regression with the ROC (Receiver Operating Characteristic) graph procedure to obtain the 
c statistic for ischemic outcome events within 90 days (a) and for major intra- and extra-cerebral 
bleedings (b) in the derivation cohort. 
 
Figure 3 
The risk of ischemic outcome events and symptomatic intracranial bleedings / major extracranial 
bleeding according to ALESSA score in the validation cohort. 
 
Figure 4 
Logistic regression with the ROC (Receiver Operating Characteristic) graph procedure to obtain the 
c statistic for ischemic outcome events within 90 days (a) and for major intra- and extra-cerebral 
bleedings (b) in the validation cohort. 
  
Table 1: characteristics of patients included in the derivation and validation cohorts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Derivation cohort 
(n=854) 
Validation cohort 
(n=994) 
p 
Age (mean, years) 76.3 ± 9.5  75.8 ± 10.1 ns 
NIHSS (mean)  8.9 ± 7.0 8.1 ± 6.4 ns 
   ns 
Sex male 398 (46.6%) 457 (46.0%) ns 
Diabetes mellitus 221 (26.0%) 201 (20.2%) 0.004 
Hypertension 676 (79.8%) 776 (78.1%) ns 
Hyperlipidemia 282 (33.4%) 361 (36.3%) ns 
History stroke/TIA 205 (24.3%) 250 (25.2%) ns 
Smoking 158 (18.7%) 171 (17.2%) ns 
Alcoholism 57 (6.7%) 50 (5.0%) ns 
History of CHF 167 (19.6%) 159 (16.0%) 0.045 
History of MI 142 (16.8) 92 (9.3%) 0.0001 
Paroxysmal AF 316 (37.0%) 456 (43.4%) 0.001 
Pacemaker 70 (8.2%) 42 (4.2%) 0.004 
rtPA and/or thrombectomy 201 (23.5%) 329 (33.0%) 0.0001 
Moderate/Severe atrial enlargement 400 (46.9%) 405 (40.7%) 0.008 
Small lesion 325 (38.1%) 379 (38.1%) ns 
    
Alessa score 3-4 295 (34.5%) 408 (41.1%) 0.04 
    
CHA2DS2-VASc     
                        2 17 (2.0%) 37 (3.7%)  
                        3 55 (6.4%) 97 (9.8%)  
                        4 105 (12.3%) 146 (14.7%)  
                        5 221 (25.9%) 254 (25.6%)  
                        6 240 (28.1%) 318 (32.0%)  
                        7 149 (17.4%) 106 (10.7%)  
                        8 60 (7.0%) 29 (2.9%)  
                        9 7 (0.8%) 7 (0.7%)  
CHA2DS2-VASc >4 677 (79.3%) 714 (71.8%) 0.0002 
    
Vitamin k antagonist 493 62 0.0001 
Direct anticoagulant 79 878 0.0001 
No anticoagulant 282 53 0.0001 
    
Table 2: Endpoints in the derivation and validation cohorts by different oral anticoagulants 
  Derivation cohort 
(n=854) 
Validation cohort 
(n=994) 
Recurrent ischemic event (90 days) 
    Ischemic stroke 
    TIA 
    Systemic embolism 
66 (7.7%) 
50 
9 
7 
27 (2.7%) 
22 
4 
1 
Hemorrhagic event (90 days) 
    Symptomatic intracranial bleeding 
    Major extracranial bleeding 
31 (3.6%) 
29 
2 
22 (2.2%) 
14 
8 
   
   
Recurrent ischemic event (at 90 days)   
Vitamin k antagonist 35/493 (7.1%) 3/62 (4.8%) 
Direct anticoagulant 4/79 (5.1%) 21/878 (2.4%) 
   
Hemorrhagic event (at 90 days)   
Vitamin k antagonist 15/493 (3.0%) 6/62 (9.6%) 
Direct anticoagulant 2/79 (2.5%) 21/878 (1.6%) 
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Area Under the Curve 0.646 (0.529-0.763), 
p=0.009 
Area Under the Curve 0.407 (0.275-0.540), 
p=0.14 
